A Multiple Enzyme‐Mimetic Platinum–Ruthenium Nanohybrid Prodrug Potentiates Chemo‐/Chemodynamic‐/Immuno‐Therapy of Hypoxic Tumors
In vitro and in vivo investigations demonstrate that PR nanohybrid exhibits superior anticancer efficacy over free Oxa and displays promising potential in combination with PD‐1 blockade therapy, offering a novel strategy to advance platinum‐based combination cancer therapy.